RT Journal Article
SR Electronic
T1 Vaccination mitigates climate-driven disruptions to malaria control
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.02.24305230
DO 10.1101/2024.04.02.24305230
A1 Rice, Benjamin L.
A1 Raobson, Estelle
A1 Miharisoa, Sylviane
A1 Rebaliha, Mahery
A1 Lewinski, Joseph
A1 Raharinirina, Hanitriniaina
A1 Greenhouse, Bryan
A1 Golden, Christopher D.
A1 Vecchi, Gabriel A.
A1 Wesolowski, Amy
A1 Grenfell, Bryan
A1 Metcalf, C. Jessica E.
YR 2024
UL http://medrxiv.org/content/early/2024/04/03/2024.04.02.24305230.abstract
AB Increasingly extreme weather events in high malaria burden areas threaten progress to disease control targets. Yet, data on the impact of these events on control programs remain rare. Using unique data from Madagascar, we estimate high rates of infection in the wake of two major tropical cyclones. Evidence that infection rebounds rapidly during gaps in interventions indicates maintaining continuity of coverage is crucial to limiting burden. Relative to other interventions, recently available malaria vaccines have a longer duration of protection, with the potential to address interruptions in prevention deployment. Evaluating this use case, we quantify the reduction in symptomatic infections expected for a range of vaccination scenarios. We find long-lasting interventions such as vaccination are a key mitigation measure against climatic disruptions to disease control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the CRS SCP4 Multisectoral Malaria Project (BLR, SM, MR), The Falcon Award for Disease Elimination - The Climate Edit by the Global Institute for Disease Elimination (GLIDE) (BLR, MR), The Ren Che Foundation and the AWS Impact Computing Project at the Harvard Data Science Initiative (HDSI) (CDG), The High Meadows Environmental Institute (HMEI) at Princeton University (BLR, GAV, CJEM) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study procedures received approval from the Institutional Review Board (IRB) of the Harvard T.H. Chan School of Public Health (IRB#21-0111), Comite d'Ethique de la Recherche Biomedicale (CERBM) at Ministere de la Sante Publique de Madagascar (No019/MSANP/SG/AMM/CERBM 2021)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are available in the main text or the supplementary materials. Data files are available at a github repository: https://github.com/bennyrice/mananjary_cyclone_code https://github.com/bennyrice/mananjary_cyclone_code